Intelligence · Clinical Development
Pipeline search results
Programs matching “aflibercept” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 79 pipeline programs matching "aflibercept" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Subconjunctival aflibercept
Regeneron UK Limited
Corneal Neovascularization
1 trial -
aflibercept
Regeneron UK Limited
Lymphoma, Non-Hodgkin
1 trial -
aflibercept (AVE0005)
Regeneron UK Limited
Neoplasms
2 trials -
aflibercept (AVE0005)
Regeneron UK Limited
Cancer
1 trial -
ziv-aflibercept
Regeneron UK Limited
Cancer
2 trials -
ziv-aflibercept
Regeneron UK Limited
Lymphoma
2 trials -
16995
Regeneron UK Limited
Neovascular Macular Degeneration
1 trial -
17508
Regeneron UK Limited
Macular Degeneration
1 trial -
17668
Regeneron UK Limited
Wet Macular Degeneration
1 trial -
Aflibercept
Regeneron UK Limited
Diabetic Retinopathy
2 trials -
Aflibercept
Regeneron UK Limited
Age Related Macular Degeneration
1 trial -
Aflibercept
Regeneron UK Limited
Diabetic Macular Edema
2 trials -
Aflibercept
Regeneron UK Limited
Exudative Macular Degeneration
1 trial -
Aflibercept
Regeneron UK Limited
Fibrovascular Pigment Epithelial Detachment
1 trial -
Aflibercept
Regeneron UK Limited
Retinal Vein Occlusion
2 trials -
Aflibercept
Regeneron UK Limited
Submacular Vascularized Pigment Epithelial Detachments
1 trial -
Aflibercept (2.0 mg)
Regeneron UK Limited
Macular Edema With Central Retinal Vein Occlusions
1 trial -
Aflibercept (BAY86-5321, Eylea)
Regeneron UK Limited
Diabetic Macular Edema
1 trial -
Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
Regeneron UK Limited
Diabetic Macular Edema (DME)
1 trial -
Aflibercept Injection
Regeneron UK Limited
Diabetic Retinopathy
2 trials -
Aflibercept Ophthalmic
Regeneron UK Limited
Wet Macular Degeneration
1 trial -
Intravitreal Aflibercept
Regeneron UK Limited
Diabetic Macular Edema
2 trials -
Intravitreal Aflibercept Injection
Regeneron UK Limited
Cystoid Macular Edema
1 trial -
Intravitreal Aflibercept Injection (IAI)
Regeneron UK Limited
Age - Related Macular Degeneration (AMD)
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.